GlassScriptPhysician profile
Mariam P Korah
NPI 1083891543
$9,172.87
in general payments reported to CMS, 2019-2025
65 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $338 · 2021: $751 · 2022: $1,039 · 2023: $1,638 · 2024: $2,232 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,184.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,087.93 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $933.44 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $920.51 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $615.55 | 2019-2025 | |
| Janssen Biotech, INC. | $396.81 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Lilly USA, LLC | $302.27 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $281.67 | 2020-2023 | Tukysa, Padcev |
| Amgen INC. | $254.03 | 2020-2025 | Nplate, Vectibix, Xgeva |
| Puma Biotechnology, INC. | $235.48 | 2020-2025 | |
| US Oncology Corporate, INC. | $220.88 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $199.38 | 2020-2025 | Libtayo |
| Sobi, INC | $185.61 | 2022-2025 | |
| Genentech USA, INC. | $178.46 | 2024-2025 | Tecentriq, Phesgo, Tecentriq Hybreza |
| Eisai INC. | $175.36 | 2021-2025 | |
| Daiichi Sankyo INC. | $160.37 | 2023-2025 | Enhertu |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Korah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.